TONIX Pharmaceuticals Holding Corp. (TNXP)

At TONIX Pharmaceuticals, we are developing new treatments for challenging disorders of the central nervous system (CNS).

The Company’s lead program is a potential new treatment for fibromyalgia and post-traumatic stress disorder, which are chronic CNS syndromes. In each of these programs, TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (FDA) and are marketed by other companies.